Incretin Atlas › Trials › PEX168 add-on to metformin phase 3b
PEX168 add-on to metformin phase 3b
PEG-loxenatide · t2d
Design
- Molecule(s)
- PEG-loxenatide
- Population
- t2d
- Phase
- 3
- Duration
- 24 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100 μg + metformin | t2d china | 24 | — | — | — | −1.2 | — | — | — | — | 0.0 vs 0.0 | — | press release |
| 200 μg + metformin | t2d china | 24 | — | — | — | −1.1 | — | — | — | — | 0.0 vs 0.0 | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (4)
- 100 μg + metformin · hba1c · publication
in the PEX168 groups (-1.16% [0.08%] and -1.14% [0.08%] with 100 and 200 μg, respectively)
- 100 μg + metformin · sae · Abstract, Results
No treatment-emergent serious adverse events occurred.
- 200 μg + metformin · hba1c · publication
in the PEX168 groups (-1.16% [0.08%] and -1.14% [0.08%] with 100 and 200 μg, respectively)
- 200 μg + metformin · sae · Abstract, Results
No treatment-emergent serious adverse events occurred.
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: PEX168 add-on to metformin phase 3b. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/pex168-add-on-to-metformin-phase-3b/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.